





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Medx-Set Limited C/O Mr. Raymond Kelly Regulatory Affairs Quality Assurance Specialist Arazy Group 56B Shawdow Drive Hudson, New Hampshire 03051

APR 2 7 2011

Re: K110282

Trade/Device Name: LIGHTY DD INFUSION SET

Regulation Number: 21 CFR 880.5440

Regulation Name: Intravascular Administration Set

Regulatory Class: II Product Code: FPA Dated: January 7, 2011 Received: January 31, 2011

Dear Mr. Kelly:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours

Anthony D. Watson, B.S., M.S., M.B.A.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation

Center for Devices and Radiological Health

K110282



Office: 3 Hasadna, Industrial Zone, Tirat Carmel 39032 Tel- 972-4-8550652 Fax - 972-4-8500297 E-Mail: info@Nilimedix.com

INDICATIONS FOR USE

510(k) Number (if kno	own):	ì			•	
Device Name:	LIGHTY DD	INFUSION	SET	·		
Indications for Use: external infusion pur		subcutaned	ous delivery of	medicine, inclu	ıding insulin	, from an
Prescription Use (Part 21 CFR 801	e <u>√</u> I Subpart D		AND/OR	Over-The-Cour (21 CFR 80	nter Use 1 Subpart C)	
(PLEASE DO NOT	WRITE BELO	OW THIS LI	NE-CONTINUE	ON ANOTHER	PAGE IF NE	EDED)
	Concurrence	of CDRH, C	office of Device	Evaluation (ODE	Ē)	
			intection Cont	Off) esthesiology, Ger rol. Dental Device	's	20/0
			อาบ(k) เขนกายย	ii. <u>1 \ 1 \ 0 \ </u>	& O C	